Sign In
Buy STTK
$4.75
-0.120 (-2.46%)
At Close: Jun 03, 2026
What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now?
01:01pm, Wednesday, 08'th Oct 2025
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel
07:51am, Thursday, 02'nd Oct 2025
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec
Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross?
10:55am, Friday, 19'th Sep 2025
Shattuck Labs, Inc. (STTK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, STTK's 50-day simple moving average crossed above
Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?
06:10pm, Monday, 08'th Sep 2025
Shattuck Labs (STTK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
06:30am, Tuesday, 26'th Aug 2025
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune dis
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
10:17am, Thursday, 21'st Aug 2025
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
06:30am, Thursday, 14'th Aug 2025
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
06:30am, Tuesday, 05'th Aug 2025
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –
Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism
07:00am, Wednesday, 02'nd Jul 2025
AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
04:20pm, Thursday, 01'st May 2025
– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
05:00pm, Wednesday, 02'nd Apr 2025
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor ne
Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
07:00am, Thursday, 27'th Mar 2025
– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-c
– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate t
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necro
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress
07:00am, Tuesday, 04'th Feb 2025
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec
